Compare XLO & RSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XLO | RSF |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.8M | 59.0M |
| IPO Year | 2021 | N/A |
| Metric | XLO | RSF |
|---|---|---|
| Price | $8.48 | $14.57 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 33.3K | 10.5K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.61% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,766,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $168.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | N/A |
| 52 Week Low | $0.46 | $14.23 |
| 52 Week High | $9.25 | $15.07 |
| Indicator | XLO | RSF |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 49.66 |
| Support Level | $0.62 | $14.34 |
| Resistance Level | $8.66 | $14.76 |
| Average True Range (ATR) | 0.50 | 0.11 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 68.13 | 37.50 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.